Dario Campana

Campana Dario

Appointment(s)
  • Professor, Department of Paediatrics
Administrative Appointment(s)
  • Director, Director, Laboratory of Immunopathology and Cell Therapy, Division of Paediatric Haematology & Oncology, National University Health System
Academic Qualifications
  • PhD, University of Milano, Italy
  • MD, University of Torino, Italy
Research Interest(s)
  • Leukaemia
  • Lymphoma
  • Cancer Immunotherapy
Recent Publications
  • 1. Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, Paolucci P, Dominici M. 2015 Sep. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget. 6(28):24884-94. doi: 10.18632/oncotarget.4670. 26298772.
  • 2. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D. 2015 Apr. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3. 25800893.
  • 3. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. 2015 Jan. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 38(1):24-36. doi: 10.1097/CJI.0000000000000059. 25415285.
  • 4. Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE. 2014 Dec. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia. 28(12):2336-43. doi: 10.1038/leu.2014.142. 24781017.
  • 5. O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE. 2013 Nov. Gemtuzumab ozogamicin can reduce minimal residual disease in childhood acute myeloid leukemia. Cancer. 119(22):4036-43. doi: 10.1002/cncr.28334. 24006085.